169 related articles for article (PubMed ID: 35988690)
1. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
[TBL] [Abstract][Full Text] [Related]
2. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor-associated macrophages.
Ke K; Lin J; Huang N; Yan L; Liao R; Yang W
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1888. PubMed ID: 37688511
[TBL] [Abstract][Full Text] [Related]
4. Ablation of Foxl1-Cre-labeled hepatic progenitor cells and their descendants impairs recovery of mice from liver injury.
Shin S; Upadhyay N; Greenbaum LE; Kaestner KH
Gastroenterology; 2015 Jan; 148(1):192-202.e3. PubMed ID: 25286440
[TBL] [Abstract][Full Text] [Related]
5. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Calderaro J; Ghaffari Laleh N; Zeng Q; Maille P; Favre L; Pujals A; Klein C; Bazille C; Heij LR; Uguen A; Luedde T; Di Tommaso L; Beaufrère A; Chatain A; Gastineau D; Nguyen CT; Nguyen-Canh H; Thi KN; Gnemmi V; Graham RP; Charlotte F; Wendum D; Vij M; Allende DS; Aucejo F; Diaz A; Rivière B; Herrero A; Evert K; Calvisi DF; Augustin J; Leow WQ; Leung HHW; Boleslawski E; Rela M; François A; Cha AW; Forner A; Reig M; Allaire M; Scatton O; Chatelain D; Boulagnon-Rombi C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Pawlotsky JM; Zhang X; Luciani A; Mulé S; Laurent A; Amaddeo G; Regnault H; De Martin E; Sempoux C; Navale P; Westerhoff M; Lo RC; Bednarsch J; Gouw A; Guettier C; Lequoy M; Harada K; Sripongpun P; Wetwittayaklang P; Loménie N; Tantipisit J; Kaewdech A; Shen J; Paradis V; Caruso S; Kather JN
Nat Commun; 2023 Dec; 14(1):8290. PubMed ID: 38092727
[TBL] [Abstract][Full Text] [Related]
6. Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.
Na HY; Kim JH; Kim H; Cho JY; Han HS; Jang ES; Kim JW; Jeong SH; Heo J; Kim JW; Kim JW; Ahn S
Histopathology; 2024 Jan; 84(2):402-408. PubMed ID: 37903726
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
8. A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.
Zhang F; Hu K; Tang B; Tian M; Lu S; Yuan J; Li M; Chen R; Ren Z; Shi Y; Yin X
J Gastrointest Surg; 2021 Apr; 25(4):971-982. PubMed ID: 32350718
[TBL] [Abstract][Full Text] [Related]
9. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
Gurzu S; Szodorai R; Jung I; Banias L
J Cancer Res Clin Oncol; 2024 May; 150(5):270. PubMed ID: 38780656
[TBL] [Abstract][Full Text] [Related]
10. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning.
Beaufrère A; Ouzir N; Zafar PE; Laurent-Bellue A; Albuquerque M; Lubuela G; Grégory J; Guettier C; Mondet K; Pesquet JC; Paradis V
JHEP Rep; 2024 Mar; 6(3):101008. PubMed ID: 38379584
[TBL] [Abstract][Full Text] [Related]
11. A Novel Mouse Model of Combined Hepatocellular-Cholangiocarcinoma Induced by Diethylnitrosamine and Loss of
Domènech Omella J; Cortesi EE; Verbinnen I; Remmerie M; Wu H; Cubero FJ; Roskams T; Janssens V
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627221
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analyses of the clinicopathological features and genomic mutations of combined hepatocellular-cholangiocarcinoma.
Ito T; Ishii T; Takeda H; Sumiyoshi S; Tomofuji K; Wakama S; Makino K; Horie H; Kumagai K; Takai A; Uebayashi EY; Ogiso S; Fukumitsu K; Haga H; Seno H; Hatano E
Hepatol Res; 2024 Jan; 54(1):103-115. PubMed ID: 37699724
[TBL] [Abstract][Full Text] [Related]
13. Combined hepatocellular cholangiocarcinoma in hepatectomy specimens: A clinicopathologic analysis.
Patil N; Sahai P; Rastogi A; Sharma N; Shasthry SM; Mukund A; Laroia ST; Kumar G; Pamecha V; Sarin SK
Indian J Pathol Microbiol; 2023; 66(4):744-750. PubMed ID: 38084526
[TBL] [Abstract][Full Text] [Related]
14. PRECLINICAL MODELS OF LIVER CÂNCER.
Galvão FHF; Traldi MCC; Araújo RSS; Stefano JT; D'Albuquerque LAC; Oliveira CP
Arq Gastroenterol; 2023; 60(3):383-392. PubMed ID: 37792769
[TBL] [Abstract][Full Text] [Related]
15. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.
Sasaki M; Sato Y; Nakanuma Y
Virchows Arch; 2024 Mar; ():. PubMed ID: 38532197
[TBL] [Abstract][Full Text] [Related]
16. Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma.
Gan X; Dong W; You W; Ding D; Yang Y; Sun D; Li W; Ding W; Liang Y; Yang F; Zhou W; Dong H; Yuan S
Cancer Lett; 2024 Jan; 581():216513. PubMed ID: 38036041
[TBL] [Abstract][Full Text] [Related]
17. Proteome Landscapes of Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Yi X; Zhu J; Liu W; Peng L; Lu C; Sun P; Huang L; Nie X; Huang S; Guo T; Zhu Y
Mol Cell Proteomics; 2023 Aug; 22(8):100604. PubMed ID: 37353004
[TBL] [Abstract][Full Text] [Related]
18. Component prediction in combined hepatocellular carcinoma-cholangiocarcinoma: habitat imaging and its biologic underpinnings.
Xiao Y; Huang P; Zhang Y; Lu X; Zhou C; Wu F; Wang Y; Zeng M; Yang C
Abdom Radiol (NY); 2024 Apr; 49(4):1063-1073. PubMed ID: 38315194
[TBL] [Abstract][Full Text] [Related]
19. Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.
Chu KJ; Kawaguchi Y; Wang H; Jiang XQ; Hasegawa K
J Clin Transl Hepatol; 2024 Feb; 12(2):210-217. PubMed ID: 38343605
[TBL] [Abstract][Full Text] [Related]
20. Comparison contrast-enhanced CT with contrast-enhanced US in diagnosing combined hepatocellular-cholangiocarcinoma: a propensity score-matched study.
Yang J; Zhang Y; Bao WY; Chen YD; Jiang H; Huang JY; Zeng KY; Song B; Huang ZX; Lu Q
Insights Imaging; 2024 Feb; 15(1):44. PubMed ID: 38353807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
